Method to determine allocation of clinical pharmacist resources

Granko, Robert P.; Poppe, Lindsey B.; Savage, Scott W.; Daniels, Rowell; Smith, Edwin A.; Leese, Peter J.

doi:10.2146/ajhp110510

Cited by 28 publications

(19 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous literature, pharmacists in the ambulatory cancer setting have been shown to be beneficial. 1,7,8,11,16–21 A descriptive report detailing the development of clinical pharmacy services in a North Carolina outpatient oncology clinic was published in 2011. 1 Interventions such as patient counseling and supportive care recommendations were similar to those demonstrated in this study; however, a Board Certified Oncology Pharmacist was utilized and interventions were not associated with cost avoidance values.…”

Section: Discussionmentioning

confidence: 99%

Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center

Randolph

Walker

Nguyen

et al. 2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To provide a foundation to justify the presence of a full-time clinical pharmacist in the ambulatory cancer center in addition to an existing centralized pharmacist through cost avoidance calculation and patient and staff satisfaction surveys. Methods The prospective, pilot study took place in an ambulatory cancer center over four weeks in 2014. Cost avoidance values were assigned to interventions performed by a pharmacy resident, who was present in the ambulatory cancer center during clinic hours, along with a centralized oncology pharmacist routinely working with the cancer center. Anonymous patient and staff satisfaction surveys based on a 5-point Likert scale were distributed to assess the perceived benefit of a pharmacist located in the ambulatory cancer center. Results Data collection took place over approximately one month. After evaluation of 962 interventions from both pharmacists, the estimated cost avoidance was US$282,741 per pharmacist per year, yielding a net benefit of US$138,441. The most common interventions made by the resident included chemotherapy regimen review (n = 290, 69%) and patient counseling (n = 102, 24%), while the majority of the centralized pharmacist's interventions was chemotherapy regimen review (n = 525, 97%). Results from the anonymous patient and staff surveys revealed an overall positive perception of the pharmacy resident while in the ambulatory cancer center. Conclusion A full-time clinical pharmacist in an ambulatory cancer center is both financially beneficial and positively perceived by patients and staff.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center

Randolph

Walker

Nguyen

et al. 2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…They may also fail to capture the full scope of work performed. One promising attempt was recently made to characterize workload in order to improve the allocation of full‐time clinical pharmacist positions 79 . This tool was intended to account for patient acuity and teaching responsibilities in addition to overall patient census; however, its use of medication cost may have inflated the need in certain areas (eg, oncology), and it could not account for emotional labor, which may not correlate with patient acuity.…”

Section: Call To Actionmentioning

confidence: 99%

Burnout among clinical pharmacists: Causes, interventions, and a call to action

Hagemann

Reed

Bradley

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

“…In 2012, Granko et al published a novel tool, pCATCH, to help guide the application of pharmacy human resources through the incorporation of patient census, patient acuity, teaching involvement, drug expenditures, and utilization of high-risk medications. 18 In 2016, Patel et al described their process of customizing an existing tool within the electronic health record to establish a comprehensive methodology to prioritize and monitor a patient's medication therapy. Overall, this tool focused on patient-specific factors, including changes in laboratory values, and assigned acuity scores to patients.…”

Section: Discussionmentioning

confidence: 99%